Baird lowered the firm’s price target on Haemonetics (HAE) to $72 from $87 and keeps an Outperform rating on the shares. The firm updated its model following its messy Q1 results which beat on weak IVT; but offsets should keep the 2026 guidance in check.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Barrington lowers Haemonetics price target, says pullback ‘too much’
- Haemonetics price target lowered to $70 from $90 at Mizuho
- Haemonetics Reports Q1 Fiscal 2026 Earnings
- Haemonetics downgraded to Neutral from Overweight at JPMorgan
- Haemonetics: Strong Plasma Performance and Growth in Blood Management Justify Buy Rating Despite Interventional Challenges